NCT03002025

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants

A Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Janssen Pharmaceutical K.K. · Industry
• Sex: Male
• Age: 20 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) following single-dose subcutaneous (SC) injection of JNJ-64304500 in healthy Japanese male participants.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-64304500	Participants will receive JNJ-64304500 as SC injection.
DRUG	Placebo	Participants will receive matching placebo to JNJ-64304500 as SC injection.

Timeline

• Start date: 2017-01-10
• Primary completion: 2017-09-09
• Completion: 2017-09-09
• First posted: 2016-12-23
• Last updated: 2025-02-03

Locations

1 site across 1 country: Japan